FDA approves AstraZeneca’s Lumoxiti for hairy cell leukaemia (HCL)
pharmafile | September 17, 2018 | News story | Sales and Marketing | AstraZeneca, HCL, Lumoxiti, leukaemia, rare diseases
AstraZeneca’s Lumoxiti has been approved for use for the treatment of relapsed or refractory hairy cell leukemia (HCL)in adults who have had at least two prior therapies for the disease.
The FDA granted the CD22-directed cytotoxin Fast Track and Priority review designations as well as Orphan Drug designation which is intended to provide incentives to assist and encourage the development of drugs for rare diseases.
The drug’s efficacy was shown in a clinical study of 80 patients who had previously been treated for HCL. The most common side effects included injection-related reactions, edema, nausea, fatigue, headache, fever, constipation, anemia, and diarrhoea.
Dr Richard Pazdur, Director of the FDA’s Office of Hematology and Oncology Products, commented in a statement that: “This therapy is the result of important research conducted by the National Cancer Institute that led to the development and clinical trials of this new type of treatment for patients with this rare blood cancer.”
Louis Goss
Related Content
AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer
AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) …